Physicians' Academy for Cardiovascular Education

Post-ACS patients are not adequately treated with high-potency statin regimens

Predictors of Non use of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

Eisen A, Cannon CP, Braunwald E, et al. - J Am Heart Assoc. 2017;6:e004332

Background

High-potency statin regimens (HPSR) reduce the risk of recurrent CV events in post-ACS patients, and ACS management guidelines recommend the use of HPSR in all patients after an ACS, regardless of their baseline lipid profile [1-4]. However, in clinical practice, HPSR are not prescribed for 50% to 70% of patients following hospitalisation due to an ACS, for reasons that are not clear [5,6].

In this study, the patient characteristics associated with non-use of an HPSR were examined in a large, multinational, contemporary, randomised trial population after ACS. An HPSR was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Of the 13 026 patients in the SOLID-TIMI 52 study, 96% had information about their statin therapy at baseline.

Main results

Conclusion

In a large, multinational, post-ACS population, most patients were not treated with high-potency statin regimens early and late after the event, including many patients at the highest risk of recurrent CV events. These findings emphasize the need of a better adherence to ACS guideline recommendations.

References

Show references

Find this article online at JAHA